Skip to main content

Table 3 Comparison of demographic and clinical characteristics in patients with and without audiographically demonstrated ototoxicity

From: Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada

 

Ototoxicity N = 30

No ototoxicity N = 47

Univariate model

Multivariate modela

OR (95%CI)

P value

OR (95%CI)

P value

Sex, female

24 (80%)

29 (61.7%)

2.48 (0.85–7.24)

0.096

4.96 (1.24–19.87)

0.024

Age (years), median (IQR)

61 (43–65)

65 (51–72)

0.98 (0.95–1.01)

0.247

0.98 (0.94–1.02)

0.297

Race

 Caucasian

22 (73.3%)

29 (61.7%)

1.71 (0.63–4.64)

0.295

  

 South Asian

1 (3.3%)

1 (2.1%)

1.59 (0.09–26.36)

0.748

  

 East Asian

6 (20%)

16 (34%)

0.48 (0.16–1.42)

0.188

0.24 (0.06–0.95)

0.042

 African

1 (3.3%)

1 (2.1)

1.59 (0.09–26.36)

0.748

  

Weekly dose AK per bodyweight (mg/kg/week), median (IQR)b

29 (23.7–41.3)

25.2 (21.8–29.4)

1.05 (1.00–1.10)

0.047

1.03 (0.98–1.09)

0.248

Months on AK, median (IQR)

11.5 (7–18.25)

7 (4–10)

1.04 (1.00–1.08)

0.052

  

Total dose AK per bodyweight (g/kg), Median (IQR)c

1.81 (0.85–3.13)

0.74 (0.51–1.27)

1.59 (1.08–2.33)

0.018

1.62 (1.08–2.43)

0.020

Total dose AK (g), Median (IQR)d

77.3 (52.9–196.3)

41.7 (25.6–67.5)

1.01 (1.00–1.02)

0.011

  

Repeated exposure to amikacin

9 (30%)

10 (21.3%)

1.59 (0.56–1.52)

0.388

  

Baseline weight (kg), Median (IQR)

51.5 (41–66.5)

55 (48–64)

0.99 (0.96–1.03)

0.712

  

Initial serum creatinine (umol/L), mean (SD)

66.0 (56.7–74.0)

63 (53–75)

1.01 (0.97–1.04)

0.656

  

Baseline disabling hearing impairment

8 (26.7%)

24 (51.1%)

0.35 (0.13–0.94)

0.037

0.54 (0.17–1.74)

0.305

Current treatment with macrolides

29 (96.7%)

45 (95.7%)

1.23 (0.11–14.87)

0.839

  

Nephrotoxicity

1 (3.6%)

4 (8.5%)

0.38 (0.04–3.58)

0.398

  
  1. IQR Interquartile Range, AK Amikacin
  2. aVariables with a p-value < 0.2 in the univariate analysis, and variables considered a priori to be clinically important, were included in the multivariate model, wherein multicollinearity was explored using variance inflation factor (VIF). Months on amikacin and total dose amikacin per bodyweight both had VIFs> 10, and so were eliminated
  3. bOR represents risk associated with each increase of 1 mg/kg/week
  4. cOR represents risk associated with each increase of 1 g/kg total dose
  5. dOR represents risk associated with each increase of 1 g total dose
  6. Total dose of amikacin and months on amikacin were excluded from the multivariate analysis due to collinearity